Physician profile
Laura Eidem
NPI 1083382204
$10,931.70
in general payments reported to CMS, 2019-2025
23 companies · $2,710 in 2025
The $2,710 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.44 · 2022: $2,189 · 2023: $3,416 · 2024: $2,587 · 2025: $2,710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,713.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,192.87 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,285.72 | 2022-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,153.13 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $767.42 | 2022-2025 | Rexulti, Abilify Mycite |
| Janssen Pharmaceuticals, INC | $583.81 | 2022-2025 | Spravato, Invega Sustenna |
| Neurocrine Biosciences, INC. | $561.38 | 2023-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $526.89 | 2023-2025 | Auvelity |
| Alkermes, INC. | $492.52 | 2022-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $441.00 | 2023-2025 | Qelbree, Qelbree |
| Corium, LLC | $421.63 | 2022-2025 | Azstarys, Azstarys |
| Tris Pharma INC | $407.54 | 2023-2024 | Dyanavel Xr, Quillichew Er, Quillivant |
| Teva Pharmaceuticals USA, INC. | $395.94 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Ironshore Pharmaceuticals INC. | $364.44 | 2022-2024 | Jornay Pm |
| Lundbeck LLC | $349.92 | 2021-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $278.18 | 2022-2025 | Fanapt, Hetlioz |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $214.15 | 2022-2024 | Quviviq |
| Noven Therapeutics, LLC | $163.32 | 2022-2024 | Xelstrym, Secuado |
| E.R. Squibb & Sons, L.L.C. | $148.36 | 2024-2025 | Cobenfy |
| Neos Therapeutics, Lp | $100.01 | 2023-2024 | Adzenys Xr-Odt |
| Collegium Pharmaceutical, INC. | $38.45 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $18.59 | 2023 | Belsomra |
| Almatica Pharma LLC | $14.76 | 2025 | Loreev Xr |
| Sunovion Pharmaceuticals INC. | $11.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Eidem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.